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Abbreviation Full Term 
LMICs Low- and middle-income countries 
ThaiPOG Thai Pediatric Oncology Group 
DCO Death Certificate Only 
ICCC International Classification of Childhood Cancer 
%MV Percent of morphologically verified cases 
%DCO Percent of cases verified by death certificate verification only 
ASR Age-standardized incidence rate 
IRR Incidence rate ratio 
APC Annual percent changes 
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ABSTRACT 
Background: Southeast Asia is undergoing a transition from infectious to chronic 
diseases, including a dramatic increase in adult cancers. Childhood cancer research 
in Thailand has focused predominantly on leukemias and lymphomas or only 
examined a short period of time. This comprehensive multi-site study examined 
childhood cancer incidence and survival rates in Thailand across all international 
classification of childhood cancer (ICCC) groups over a 20-year period. 
Methods: Cancer cases diagnosed in children ages 0-19 years (n=3,574) from 
1990-2011 were extracted from five provincial population-based Thai registries, 
covering approximately 10% of the population. Descriptive statistics of the quality of 
the registries were evaluated. Age-standardized incidence rates were calculated 
using the Segi world standard population, and relative survival was computed using 
the Kaplan-Meier method. Changes in incidence and survival were analyzed using 
Joinpoint Regression and reported as annual percent changes (APC).  
Results: The age-standardized incidence rate of all childhood cancers during the 
study period was 98.5 per million person-years with 91.0 per million person-years in 
1990-2000 and 106.2 per million person-years in 2001-2011. Incidence of all 
childhood cancers increased significantly (APC=1.2%, p<0.01). The top three cancer 
groups were leukemias, brain tumors, and lymphomas. The 5-year survival for all 
childhood cancers significantly improved from 39.4% in 1990-2000 to 47.2% in 2001-
2011 (p<0.01). 
Conclusions: Both childhood cancer incidence and survival rates have increased, 
suggesting improvement in the healthcare system as more cases are identified and 
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treated. Analyzing childhood cancer trends in low- and middle-income countries can 
improve understanding of cancer etiology and pediatric healthcare disparities 
 
 
INTRODUCTION 
 While childhood cancer remains relatively rare compared to adult cancers, a 
childhood cancer diagnosis is a major medical and psychological stressor with lifelong 
impacts, even in the context of increasing survival rates. Whereas comprehensive registries 
in many high-income countries capture incidence and survival rates, global incidence and 
survival rates of childhood cancers remain less well understood. A global study of childhood 
cancers across 62 different regions found that the age-standardized incidence rate (ASR) 
was 140.6 per million person-years in children 0-14 years, with the most common cancers 
being leukemias, central nervous system tumors, and lymphomas.1 The ASR increased from 
124.0 per million person-years in the 1980s to 140.6 per million person-years in years 2001-
2010.1 Over 90% of deaths due to childhood cancer occur in low- and middle-income 
countries (LMICs), illustrating how countries with limited resources are confronted with major 
healthcare challenges in treating pediatric cancer.2,3 Additionally, deaths due to childhood 
cancer are increasing in developing regions.4 While 80% of young patients with cancer in 
Africa are likely to die, 80% in high-income countries survive.5 A combination of factors, 
including later diagnosis, limited access to imaging facilities and treatment options, and 
population-specific genetic and environmental risk factors likely contribute to this disparity 
between developed and developing countries.5  
 In recent decades, many LMICs—including Thailand—have undergone an 
epidemiologic transition, during which disease burden has largely shifted from infectious to 
chronic.6 Many research efforts focus on adult cancer rates, but less is known about 
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pediatric cancers in Thailand. In 2001, pediatric oncologists formed the Thai Pediatric 
Oncology Group (ThaiPOG) to standardize treatment protocols for diagnosis and treatment 
of childhood cancers in Thailand.7 ThaiPOG published a report of 999 new cancer cases 
from 20 cancer registry centers in 2003 with leukemias being the most commonly diagnosed 
cancer group (42.6% of the cases).8 While this report provided a snapshot of the incidence 
of pediatric cancers during one year, the report could not elucidate trends of diagnoses or 
survival over time to better understand childhood cancer burden in Thailand. 
 Previous research has shown that overall incidence of childhood cancer in Thailand 
was lower than in high-income countries, but incidence rates increased 32.5% from 1988-
1994 to 1995-1997.9 Similar to other regions in the world, leukemias, brain tumors, and 
lymphomas made up the majority of the cases, and there was a peak for incidence between 
ages 1 and 5 years.1,9,10 Leukemia incidence and survival rates in southern Thailand 
increased between 1990 and 2011 but remained lower than in the United States.11 As 
Thailand continues to develop and disease burden shifts to non-communicable illnesses, 
cancer trends may become increasingly similar to high-income regions. Understanding these 
changing trends and disparities in childhood cancer between developed countries and 
LMICs may provide insights to biological and environmental causes of pediatric cancers, 
resulting in greater potential to influence clinical guidelines and health policy. 
 The present study reports the overall burden of all childhood cancer (cases occurring 
in children ages 0-19) in Thailand from 1990 to 2011. By analyzing both incidence and 
survival trends from registry data for all cancer cases by sex, age group, and cancer type, 
we can better understand the burden of childhood cancer in Thailand and predict future 
diagnostic and survival rates.  
 Childhood Cancer Incidence & Survival in Thailand 
 
This article is protected by copyright. All rights reserved. 
 
6 
METHODS 
Study population 
 Childhood cancer cases diagnosed between 1990 and 2011 were extracted from five 
population-based cancer registries in Thailand located in Chiang Mai, Lampang, Khon Kaen, 
Songkhla, and Surat Thani (Fig. 1). In each hospital or medical center that contributed to 
these registries, cases were determined from medical records, pathology reports, imaging 
reports, and hospital tumor registries using a nationally standardized form.12 These data 
forms were checked for duplication and entered into a database using the International 
Association of Cancer Registry’s CanReg software program.12 
 Thailand cancer registries utilize both active and passive follow-up methods and 
track the vital status of cases from the hospital at which they were treated. 12 Children may 
move outside the original catchment area, so unique national personal identification 
numbers are used to track patients. In addition to registry-based diagnosis data, mortality 
records and the national death registry from Provincial Chief Medical Offices at the Ministry 
of Public Health were used to supplement case information.12 Death certificates were 
reviewed and matched with case records at each registry, and cases that were unable to be 
traced were registered as diagnosed by death certificate only (DCO).13 
 
Data extraction and variables 
Childhood cancer cases were identified using ICD-O-3 histology and site codes and 
categorized into international classification of childhood cancer (ICCC) groups.14 Twelve 
ICCC groups were included: leukemias, lymphomas, brain and spinal neoplasms, 
neuroblastomas, retinoblastomas, renal tumors, hepatic tumors, malignant bone tumors, soft 
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tissue sarcomas, gonadal and germ cell tumors, malignant epithelial tumors and 
melanomas, and other and unspecified malignant neoplasms.15 For each case, the data 
contained a registry identification number, date of birth, age, sex, date of diagnosis, date of 
last contact (alive or dead), site of cancer, histology, method of diagnosis, extension of 
cancer, and number of primary tumors.12 
Population denominator data for incidence rate calculations came from the Thailand 
population censuses in 1990, 2000, and 2010 conducted by the National Statistical Office. 
These censuses provided annual estimates by age group (0-4, 5-9, 10-14, and 15-19 years) 
and sex in Thailand.13 In between census years, populations were estimated using a log-
linear function between the two adjacent census values, and populations beyond 2010 were 
estimated and reported by the Office of the National Economic and Social Development 
Board.16 
 
Statistical analysis 
Data quality was measured as the percentage of cases morphologically verified 
(%MV), meaning cases diagnosed based on histology results, and as the percentage of 
death certificate only (%DCO) cases.12 Since data from Surat Thani were only available in 
years 2001-2009, sensitivity analyses were conducted both with and without these cases to 
determine the effect on incidence and survival trends. 
Descriptive analyses, including case counts and age-specific rates, were conducted 
to evaluate the distribution of childhood cancer types. Age-standardized incidence rates 
(ASRs) were calculated for each cancer group and were standardized using the Segi world 
standard population estimates. Incidence rates are presented in cases per million by decade 
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of diagnosis, sex, and age at diagnosis. Incidence rate ratios (IRRs) were used to compare 
the ASRs. 
Analysis of incidence trends was completed using Joinpoint Regression Program 
version 4.0.4. This allowed for examination of trends using log-linear models and computed 
annual percent changes (APC) in age-standardized incidences. Permutation tests 
determined the appropriate number of joinpoints (years of trend change), the slope of trends 
between joinpoints, and significance. The Joinpoint Regression Program does not allow for 
years with zero case counts. Therefore, if no cases were present for a given year, a half-
case was added to the age group with the largest population.11 If more than three half-case 
corrections were needed for a given ICCC group or subgroup, the APC was not computed. 
Relative survival was evaluated using mortality and life tables from the National 
Statistics Office in Thailand from 1990 to 2011. Survival analyses excluded cases if their 
basis of diagnosis was death certificate only or unknown, if they did not contain any follow-
up information, or if they had an unknown vital status. To analyze relative survival rates, the 
survival package in R was used. Relative survival results were computed using the Ederer II 
method, and survival functions were produced by the Kaplan-Meier survival method. Log-
rank tests compared relative survival by sex, decade of diagnosis, and age group. One- and 
five-year relative survival rates were computed for each ICCC group from 1990 to 2011. 
These relative survival trends were then analyzed using Joinpoint Regression under a 
piecewise linear model. 
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RESULTS 
Data Quality 
In total, 3,574 childhood cancer cases were reported between 1990 and 2011. The 
Chiang Mai registry contributed the largest proportion of cases (30.2%), while Surat Thani, 
the newest registry (with only nine years of data), contributed the fewest (6.8%) (Table 1). 
Including cases from Surat Thani did not significantly affect the trend analyses. Overall, 
86.1% of the cases were verified histologically, and only 4.2% were diagnosed by death 
certificate only (DCO). Songkhla had the highest %MV at 89.9%, while Surat Thani had the 
lowest (%MV=75.4%). Between the first and second decade of diagnosis, case counts 
increased, morphologically verified cases increased by 1.2% and DCO cases decreased by 
about 1.1%. The youngest and oldest age groups (0-4 years and 15-19 years) contributed 
the most cases to the dataset (28.0% and 30.9%, respectively), while cases that were 
diagnosed at 5-9 years of age only contributed to 19.0% of the dataset. Case counts were 
highest for leukemias (34.8%), brain and spinal neoplasms (12.3%) and lymphomas 
(11.2%). After cases with ambiguous vital status or diagnosed by DCO or autopsy were 
removed, there were 3,379 cases (94.5% of the total cases) included in the survival 
analyses.  
 
Incidence Analyses 
The age-standardized incidence rate (ASR) from 1990 to 2011 for all cancer groups 
was 98.5 per million person-years (Table 2). Leukemias, brain and spinal neoplasms, and 
lymphomas were the three most prevalent cancer groups overall, with ASRs of 36.1, 12.0, 
and 10.3 cases per million person-years, respectively. Additionally, the age-specific 
incidence rates varied by age at diagnosis, with the greatest incidence rate in cases 
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diagnosed at 0-4 years (123.7 cases per million person-years) and the lowest age-specific 
incidence rate in patients diagnosed at 5-9 years (73.1 cases per million person-years). 
From the first decade (1990-2000) to the second decade (2001-2011), the ASR of all cancer 
groups combined increased from 91.0 to 106.2 per million person-years (Table 2). The IRR 
of childhood cancers diagnosed in the second decade compared to the first decade was 1.2 
(95% CI: 1.1, 1.3). 
In males, the overall ASR for all cancer groups was 104.8 per million person-years 
for the entire study period (Table 2). The three highest ICCC group ASRs among males 
were for leukemias, lymphomas, and brain and spinal neoplasms, with values of 40.8, 13.6, 
and 12.7 per million person-years, respectively. In females, the overall ASR for all cancer 
groups throughout the entire study period was 91.8 cases per million person-years. 
Leukemias, brain and spinal neoplasms, and gonadal/germ cell neoplasms had the highest 
ASRs for females, with values of 31.2, 11.4, and 8.6 per million person-years, respectively. 
Overall, the IRR of female cancer cases to male cancer cases was 0.8 (95% CI: 0.8, 0.9). 
The ASRs for neuroblastomas, soft tissue sarcomas, gonadal/germ cell tumors, and 
carcinomas and epithelial neoplasms were higher in females than males. 
Based on Joinpoint Regression results, overall pediatric cancer incidence increased 
significantly by 1.2% (95% CI: 0.8, 1.7) each year (Table 3). Additionally, incidence of 
leukemias and gonadal and germ cell neoplasms increased annually, by 1.5% (95% CI: 0.5, 
2.5) and 2.4% (95%CI: 0.1, 4.9). For all cancer groups combined, male and female 
incidence trends are parallel (p>0.05) , but they are not coincident (p<0.01). Joinpoint 
Regression analyses suggested multiple trends to best fit the male incidence data. While 
early years in the study period fluctuated between decreasing and increasing trends, the 
only significant trend was an annual increase of 8.0% in years 2007-2011 (95% CI: 0.6, 
15.9). Overall, the average APC for males 1990-2011 was 1.8 (95% CI: -0.9, 4.5). 
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Leukemias and gonadal and germ cell neoplasms both increased significantly for males, with 
an annual increase of 1.6% (95% CI: 0.3, 3.0) and 5.3% (95% CI: 1.3, 9.6). In females, the 
APC was 1.0% (95% CI: 0.3, 1.7). Leukemias were the only ICCC group for females that 
showed a significant annual change, with an increase of 1.4% per year (95% CI: 0.1, 2.7). 
While both males and females had significant annual increases in incidence of leukemias, 
the trends were not coincident (p<0.01). 
 
Survival Analyses 
The five-year relative survival for all childhood cancers was 43.1% (95% CI: 41.1, 
45.2) (Table 4). The highest and lowest five-year relative survival rates were for renal tumors 
at 71.1% (95% CI: 61.1, 82.7) and neuroblastomas at 20.6% (95% CI:12.7, 33.3), 
respectively. Relative survival significantly increased (p<0.01) from the first decade (39.4%, 
95% CI: 36.7, 42.2) to the second decade (47.2%, 95% CI: 44.3, 50.3). Five-year relative 
survival was higher in 2001-2011 than 1990-2000 for all ICCC groups except brain and 
spinal neoplasms, gonadal and germ cell tumors, and bone tumors. However, in all groups 
and subgroups with lower survival in the second decade, the change was not significant. The 
one-year survival rate for all childhood cancers was 70.1% (95% CI: 68.5, 71.8) 
(Supplementary Table S1), with higher one-year survival rates in the second decade (73.5% 
(95% CI: 71.4, 75.7)) compared to the first decade (66.1% (95% CI: 63.6, 68.6)) and higher 
survival rates in females (72.4% (95%CI: 70.1, 74.8)) compared to males (68.2% (95% CI: 
65.9, 70.5)). 
Five-year relative survival of all ICCC groups combined was relatively the same for 
all age groups, ranging from 40.7% (95% CI: 36.2, 45. 7) for 5-9 years at diagnosis to 44.4% 
(95% CI: 40.7, 48.4) for 0-4 years at diagnosis. Age groups 0-4 years showed a significant 
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improvement in survival change per year (Supplementary Table S2). One-year relative 
survival increased 1.3% each year (95% CI: 0.8, 1.8) for cases diagnosed at 0-4 years; and 
five-year relative survival increased 1.0% each year (95% CI: 0.4, 1.7) for the same age 
group. Relative survival was coincident between age groups 0-4 and 15-19 years and 
between age groups 5-9 and 10-14 years. 
The relative survival of females for all ICCC groups combined was significantly higher 
than for males (p<0.01). For all cancer groups combined, females had a relative five-year 
survival of 49.2% (95% CI: 46.3, 52.5) while males had a relative survival of 37.7% (95% CI: 
35.0, 40.5) (Table 4). One-year and five-year relative survival rates in both males and 
females increased significantly per year (Fig. 2). One-year survival increased by 0.8% per 
year (95% CI: 0.4, 1.2) for males and increased by 0.7% per year (95% CI: 0.3, 1.2) for 
females when examining the full years of follow-up data (Supplementary Table S2). Five-
year survival increased by 1.1% per year (95% CI: 0.3, 1.8) for males and 0.9% per year 
(95% CI: 0.1, 1.7) for females. We observed that survival trends between males and females 
were parallel (p>0.05), meaning both male and female trends have similar slopes. However, 
the trends between males and females for all survival intervals were not coincident or equal 
(p<0.05). Therefore, despite the difference in survival rates for males and females, the 
changes to survival trends were occurring similarly in males and females. When analysis of 
survival was restricted to the 1990-2006 cohort, which has full five-year follow-up, we 
observed similar and consistent results (Supplementary Table S2).  
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DISCUSSION 
Using data from five high-quality population-based cancer registries in Thailand, we 
report incidence and survival rates of cancer in children ages 0-19 years from 1990 to 2011. 
Over 86.1% of the cases were verified histologically, indicating the robust data quality of the 
cancer registries. The overall ASR for all cancer groups was 98.5 cases per million person-
years, and the top three cancer groups were leukemias, brain tumors, and lymphomas. 
Cancer incidence increased significantly each year during the study period. Five-year 
relative survival across all cancers was 43.1%, with females typically having higher rates of 
survival than males. One-year and five-year relative survival rates were generally increasing 
from the first to second decade, with significant gains in each leukemia subgroups (ALL, 
AML, unspecified), Burkitt’s lymphoma, overall lymphomas ICCC gorup, and other and 
unspecified neoplasms. The few cancer groups that showed decreasing trends in survival 
were not statistically significant. 
Leukemias contribute roughly one-third of the pediatric cancer cases in Thailand. 
ALL is most common, with an ASR of 22.2 per million person-years, and AML has an ASR of 
7.8 per million person-years. Both AML and ALL incidence rates were increasing significantly 
per year, but AML was increasing at a faster rate (APC: 2.63%, 95% CI: 0.31, 5.01) 
compared to ALL (APC: 1.35%, 95% CI: 0.13, 2.58). Similar to incidence trends, the 5-year 
relative survival was higher in ALL at 44.2% (95%CI: 40.0, 48.7) than AML at 22.1% (95% 
CI: 17.0, 28.8). Both ALL and AML survival rates were increasing significantly by decade of 
diagnosis (p<0.05). 
Germ cell tumor incidence showed a significant increase in the male population, with 
an APC of 5.3%. While our analysis is unable to draw conclusions about the cause of this 
increase in only the males, we cannot rule out that these cases were previously undetected 
and therefore underreported in earlier time periods.  
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A previous Thai study examining data between 1995-1997 found comparable rates of 
incidence.9 This study used data from four of the same registries (Khon Kaen, Chiang Mai, 
Lampang, and Songkhla) but also included an additional registry in Bangkok. We elected not 
to utilize the Bangkok registry due to the fluidity of the population and difficulty in obtaining 
accurate underlying population estimates. Similar to the findings in this study, leukemias, 
central nervous system neoplasms, and lymphomas were the most common childhood 
cancers. Additionally, an examination of childhood leukemia in Songkhla and the United 
States showed similar incidence rates and trends as our report of Thai registries.11 The 
population composition in Songkhla is unique compared to other regions; select religious 
groups in this region show significantly different rates of adult cancer.17 Population and 
cultural factors such as these may impact incidence and survival.  
Thai childhood cancer rates were similar to those in other Asian countries. In Taiwan, 
the ASR for all childhood cancers cases diagnosed 1996-2010 in children 0-14 years was 
121.7 per million, and, in China, childhood cancer patients diagnosed 2000-2010 ages 0-14 
years had an ASR of 87.1 per million.18,19 The ASR in Taiwan has been increasing at the 
same rate as in Thailand, 1.2% per year, while China’s childhood cancer incidence rate is 
increasing at 2.8% annually.18,19 A global study evaluating 5-year survival rates of childhood 
leukemia patients found that patients in Thailand have lower survival rates than comparable 
populations in Taiwan, Japan, Malaysia, Korea, and India.20 
Despite the increases in both incidence and survival in Thailand, high-income 
countries, including the United States, continue to show higher childhood cancer incidence 
and survival rates.1,11 The lower incidence in Thailand may be driven by lack of access to 
diagnostic and imaging facilities and other shortages in healthcare resources. Not only does 
childhood cancer infrastructure differ between developed and developing countries, but there 
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are also clinical training and awareness differences which may prime physicians in high-
income countries to look for signs of cancer earlier than physicians in developing countries. 
 While the ecological nature of a registry analysis does not provide opportunity for 
evaluation of potential risk factors, making us unable to discern if evolving trends are due to 
changes in risk factors, diagnostic factors, or external causes, the registry data did offer a 
large sample size covering several years. The registries may have been less precise in the 
first decade compared to the second decade, but including data over a longer period of time 
allows for more robust trend analysis. Additionally, establishment of population-based cancer 
registries and a network of cancer surveillance systems has been a priority of the Thai 
government. These registries have been working to identify cases from their regional 
hospitals, outpatient care centers, and diagnostic labs for multiple decades. The data has a 
low rate of death certificate only cases and a high rate of histologically confirmed cases, 
indicating high-quality data. It is also possible that registries missed cases. However, this 
was minimized by two factors: 1) Thailand offers universal healthcare, so most Thai citizens 
are likely to use some form of health services, and 2) registry data were collected from 
several different sources to optimize case ascertainment.   
 Increasing childhood cancer incidence and survival rates may suggest improvements 
in pediatric cancer detection, diagnosis, and treatment. Thailand also experienced several 
socioeconomic changes during the study period, including the introduction of universal 
healthcare, which may positively impact case reporting and treatment. Following the 
adoption of universal healthcare, utilization of health services in Thailand has increased, 
specifically for low-income, unemployed, or chronically-ill patients.21 Patient populations who 
may have previously gone undetected are more likely to seek healthcare services. Other 
changes, such as increasingly Westernized diets and automobile pollution, could also be 
impacting incidence rates. With mortality and morbidity burden related to childhood cancer 
 Childhood Cancer Incidence & Survival in Thailand 
 
This article is protected by copyright. All rights reserved. 
 
16 
increasing worldwide, it is important to better understand disease trends to effectively 
diagnose and treat those affected by the range of childhood cancers. This work provides the 
foundation for understanding the burden of childhood cancer in Thailand, and registry 
analyses will continue to offer insights to cancer diagnosis and treatment programs. 
While our work contributes to understanding the incidence and survival of childhood 
cancer in Thailand, future investigations of specific risks and nuances of different cancer 
types may clarify causal links. Future research in LMICs should continue to examine risk 
factors for cancer occurrence and death, as well as examine predictors of late sequelae of 
treatment, to broaden the knowledge of global childhood cancer and improve medical 
protocols worldwide. 
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LEGENDS 
TABLE 1 Case counts, case frequencies, and quality of registry data by descriptive factors. 
TABLE 2 Age-specific and age-standardized incidence rates (ASRs) for ICCC groups and 
subgroups. Incidence by age at diagnosis was calculated using age-specific rates, 
while overall incidence, incidence by decade of diagnosis, and incidence by sex were 
calculated using age-standardized rates. ASRs are represented as rates per million 
person-years. 
TABLE 3 Annual percent change (APC) in incidence by ICCC group, subgroup, and sex. 
APC (% (95% CI)) was evaluated using log-linear models from Joinpoint Regression 
analyses. An asterisk (*) denotes a p-value <0.05 and 0.5 cases were added to age 
groups with the largest population when there were no cases of that ICCC group or 
subgroup for a given year. If more than three 0.5-case corrections were needed, the 
APC was not computed. 
TABLE 4 Five-year relative survival (% (95% CI)) for ICCC groups and subgroups. Relative 
survival was calculated using the Kaplan-Meier method. Overall five-year relative 
survival is shown for ICCC groups and subgroup along with five-year relative survival 
by age at diagnosis, decade of diagnosis, and sex. 
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FIGURE 1 Map of Thailand showing the five provinicial population-based registries from 
which childhood cancer cases diagnosed 1990-2011 were extracted.  
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FIGURE 2 Relative survival rates of all ICCC groups combined are shown for males, 
females, and both sexes together. Blue denotes males, red denotes females, and 
black denotes both sexes combined. Beta values represent the amount of change in 
survival per year. One-year relative survival (A) and five-year relative survival (B) are 
both significantly increasing per year for males, females, and both sexes together. An 
asterisk (*) denotes a p-value <0.05. 
 
 
SUPPLEMENTARY TABLE S1 One-year relative survival (% (95% CI)) for ICCC groups and 
subgroups. Relative survival was calculated using the Kaplan-Meier method. Overall 
one-year relative survival is shown for ICCC groups and subgroup along with one-
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year relative survival by age at diagnosis, decade of diagnosis, and sex. 
SUPPLEMENTARY TABLE S2. One- and five-year relative survival (% (95% CI)) by sex and 
age at diagnosis with full (1990-2011) and restricted (1990-2006) cohorts. The 
percent change in one- and five-year relative survival per year is shown for the 
restricted cohort (A), in which one-and five-year survival have the same follow-up 
years. Relative survival by sex is also shown using the full cohort, in which all 
available follow-up data are used for one-year survival (B). Percent change in relative 
survival per year by age group at diagnosis is also shown with the restricted cohort 
(C) and with the full cohort (D). 
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TABLE 1 Case counts, case frequencies, and quality of registry data by descriptive factors 
 
 
Cases (%) %MV1 %DCO2 
Registry 
         Chiang Mai 1,080 30.2 87.1 2.7 
     Khon Kaen 970 27.1 84.4 3.8 
     Lampang 435 12.2 86.2 4.6 
     Songkhla 845 23.6 89.9 3.9 
     Surat Thani 244 6.8 75.4 12.7 
Sex 
         Male 1,939 54.3 86.2 4.6 
     Female 1,635 45.7 86.1 3.7 
Decade of Diagnosis 
        1990-2000 1,645 46.0 85.5 4.8 
     2001-2011 1,929 54.0 86.7 3.7 
Age at Diagnosis (Years) 
        0-4 1,002 28.0 87.1 3.9 
     5-9 678 19.0 86.0 4.0 
     10-14 790 22.1 86.7 4.1 
     15-19 1,104 30.9 85.0 4.7 
ICCC3 Group     
     Leukemias 1,245 34.8 98.6 1.4 
     Lymphomas 402 11.2 99.8 0.2 
     Brain and Spinal Neoplasms 440 12.3 58.0 6.8 
     Neuroblastomas 96 2.7 99.0 0.0 
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     Retinoblastomas 76 2.1 98.7 0.0 
     Renal Tumors 94 2.6 81.9 1.1 
     Hepatic Tumors 78 2.2 48.7 9.0 
     Malignant Bone Tumors 190 5.3 91.6 3.7 
     Soft Tissue Sarcomas 178 5.0 100.0 0.0 
     Gonadal and Germ Cell Neoplasms 248 6.9 93.1 0.0 
     Malignant Epithelial Neoplasms 307 8.6 99.7 0.0 
     Other and Unspecified Neoplasms 220 6.1 0.1 39.1 
All Registries, 1990-2011 3,574 100.0 86.1 4.2 
1
 %MV is the percent of cases morphologically verified 
2
 %DCO is the percent of cases diagnosed by death certificate only 
3
 International Classification of Childhood Cancer 
 
TABLE 2 Age-specific and age-standardized incidence rates (ASRs) for ICCC groups and subgroups by age at 
diagnosis, decade of diagnosis, and sex 
ICCC Group 
Overall
1 
Age at Diagnosis
2 
Decade of Diagnosis
1
 Sex
1
 
0-4 
Year
s 
5-9 
Year
s 
10-
14 
Year
s 
15-
19 
Year
s 
1990
-
2000 
2001
-
2011 
IR
R 
95
% 
CI 
Male 
Femal
e 
IR
R 
95
% 
CI 
I. LEUKEMIA 36.1 55.9 31.4 27.7 23.3 33.4 38.9 1.2 
1.0, 
1.3 
40.8 31.2 0.7 
0.7, 
0.8 
     Acute 
lymphoblastic 
leukemia 
22.2 37.2 22.8 14.9 8.9 21.2 23.2 1.1 
1.0, 
1.3 
25.8 18.5 0.7 
0.6, 
0.8 
     Acute myeloid 
leukemia 
7.8 9.5 5.4 8.0 7.9 6.3 9.2 1.4 
1.1, 
1.8 
8.2 7.4 0.9 
0.7, 
1.1 
     Unspecified 4.8 8.4 2.6 3.2 4.2 4.8 4.9 1.0 
0.7, 
1.3 
5.2 4.4 0.8 
0.6, 
1.1 
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II. LYMPHOMA 10.3 6.4 9.8 10.7 15.5 9.5 11.1 1.2 
1.0, 
1.5 
13.6 6.8 0.5 
0.4, 
0.6 
     Hodgkin 
lymphoma 
2.0 0.6 2.5 2.4 3.1 1.5 2.5 1.7 
1.1, 
2.7 
3.1 1.0 0.3 
0.2, 
0.5 
     Non-hodgkin 
lymphoma 
5.2 1.9 5.1 6.0 9.0 4.2 6.2 1.5 
1.1, 
2.0 
6.5 3.8 0.6 
0.4, 
0.8 
     Burkitts lymphoma 0.9 1.2 1.4 0.5 0.4 0.9 1.0 1.1 
0.6, 
2.2 
1.5 0.3 0.2 
0.1, 
0.5 
     Unspecified 1.4 0.9 0.6 1.6 2.7 1.7 1.0 0.6 
0.3, 
1.0 
1.8 0.9 0.5 
0.3, 
0.9 
III. BRAIN AND 
SPINAL NEOPLASMS 
12 12.3 14.6 12 8.9 11.1 13.0 1.2 
1.0, 
1.4 
12.7 11.4 0.9 
0.7, 
1.0 
     Astrocytomas 3.1 2.7 3.2 3.0 3.7 2.8 3.5 1.3 
0.9, 
1.9 
3.1 3.2 1.0 
0.7, 
1.4 
     PNETs and 
medulloblastoma 
2.8 3.8 3.4 2.8 0.5 2.8 2.7 1.0 
0.6, 
1.5 
3.1 2.4 0.7 
0.5, 
1.1 
     Unspecified 5.0 4.3 6.7 5.0 3.9 4.9 5.1 1.1 
0.8, 
1.4 
5.3 4.6 0.8 
0.6, 
1.1 
IV. 
NEUROBLASTOMA 
3.2 8.2 2.0 0.5 0.6 3.5 2.9 0.8 
0.6, 
1.2 
2.7 3.7 1.3 
0.9, 
1.9 
V. 
RETINOBLASTOMA 
2.7 8.5 0.6 0.1 0.0 2.5 3.0 1.2 
0.8, 
1.9 
2.7 2.8 1.0 
0.6, 
1.6 
VI. RENAL TUMORS 3.2 9.0 1.5 0.2 0.5 2.5 4.0 1.6 
1.0, 
2.4 
3.2 3.3 1.0 
0.7, 
1.5 
VII. HEPATIC 
TUMORS 
2.2 3.3 1.4 0.9 2.9 2.2 2.2 1.0 
0.6, 
1.5 
2.9 1.5 0.5 
0.3, 
0.8 
VIII. MALIGNANT 
BONE TUMORS 
4.5 1.1 2.0 7.7 8.7 4.4 4.7 1.1 
0.8, 
1.4 
5.3 3.8 0.7 
0.5, 
0.9 
IX. SOFT TISSUE 
SARCOMAS 
4.8 5.3 2.7 4.3 6.8 4.3 5.2 1.3 
0.9, 
1.7 
4.5 5.1 1.1 
0.8, 
1.5 
     Rhabdomyosarco
ma 
1.8 3.2 1.2 1.4 1.2 2.0 1.7 0.9 
0.5, 
1.5 
1.9 1.7 0.9 
0.5, 
1.5 
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     Other specified 1.7 1.2 1.0 1.4 3.6 1.3 2.1 1.5 
0.9, 
2.5 
1.3 2.1 1.6 
1.0, 
2.6 
X. GONADAL AND 
GERM CELL 
NEOPLASMS 
6.2 3.8 2.4 6.7 13.0 5.5 6.8 1.2 
0.9, 
1.6 
3.8 8.6 2.2 
1.7, 
2.9 
XI. CARCINOMAS 
AND EPITHELIAL 
NEOPLASMS 
7.2 1.7 2.4 7.2 20.0 6.5 8.0 1.2 
1.0, 
1.6 
6.1 8.3 1.3 
1.1, 
1.7 
XII. OTHER AND 
UNSPECIFIED 
NEOPLASMS 
6.0 8.0 2.3 4.3 9.2 5.6 6.4 1.2 
0.9, 
1.5 
6.7 5.3 0.8 
0.6, 
1.0 
All Cancer Groups 98.5 
123.
7 
73.1 82.2 
109.
4 
91.0 
106.
2 
1.2 
1.1, 
1.3 
104.
8 
91.8 0.8 
0.8, 
0.9 
 
1 Age-standardized incidence rates calculated per 1,000,000 person-years 
2 Age-specific incidence rates 
 
 
TABLE 3 Annual percent change (APC) in incidence by ICCC group, subgroup, and sex 
ICCC Group 
Overall 
APC (95% CI) 
By Sex 
APC (95% CI) 
Males Females 
I. LEUKEMIA 1.5* (0.5, 2.5) 1.6* (0.3, 3.0) 
1.4* (0.1, 
2.7) 
     Acute lymphoblastic leukemia 1.4* (0.1, 2.6) 1.3 (-0.2, 2.8)  
1.7 (-0.3, 
3.6)  
     Acute myeloid leukemia 2.6* (0.3, 5.0) 2.9* (0.2, 5.8)  
2.1 (-0.7, 
5.0)  
     Unspecified -1.6 (-4.5, 1.4)  -0.0 (-3.6, 3.7)  
-2.6 (-6.4, 
1.4)  
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II. LYMPHOMA 1.4 (-0.1, 2.9) 1.5 (-0.3, 3.3) 
1.1 (-1.4, 
3.7) 
     Hodgkin lymphoma 3.9* (1.1, 6.8)  2.5 (-0.4, 5.6)  N/A 1 
     Non-Hodgkin lymphoma 3.5* (1.1, 6.0)  3.4*(0.6, 6.3)  
4.1* (0.1, 
8.1)  
     Burkitt lymphoma -0.2 (-3.6, 3.4)  -1.5 (-5.3, 2.4)  N/A 1 
     Unspecified 
-5.8* (-8.8, -
2.7) 
-4.2* (-7.5, -0.7)  N/A 1 
III. BRAIN & SPINAL NEOPLASMS 0.6 (-1.1, 2.3) 1.2 (-0.7, 3.4) 
0.2 (-2.5, 
3.0) 
     Astrocytomas 1.8 (-0.5, 4.1) 4.9* (1.3, 8.6)  
0.7 (-4.2, 
5.9)  
     PNETs and medulloblastoma 0.3 (-3.0, 3.7)  1.3 (-2.9, 5.7) 
-1.2 (-5.3, 
3.1) 
     Unspecified -1.2 (-3.7, 1.5)  -1.9 (-5.0, 1.4) 
-0.4 (-4.0, 
3.4)) 
IV. NEUROBLASTOMA 0.1 (-2.8, 3.0) -1.8 (-6.9, 3.5) 
0.4 (-2.2, 
3.1) 
V. RETINOBLASTOMA 0.5 (-2.9, 4.0) 4.4 (-1.1, 10.2) 
-2.2 (-6.5, 
2.3) 
VI. RENAL TUMORS 2.5 (-2.0, 7.2) 2.0 (-2.7, 6.9) 
2.8 (-2.3, 
8.1) 
VII. HEPATIC TUMORS -1.6 (-5.2, 2.0) 0.4 (-4.4, 5.5) 
-2.4 (-7.6, 
3.1) 
VIII. MALIGNANT BONE TUMORS 0.7 (-1.7, 3.1) -0.5 (-4.0, 3.2) 
1.4 (-2.6, 
5.7) 
IX. SOFT TISSUE SARCOMAS 1.2 (-0.7, 3.1) -0.2 (-3.4, 3.2) 
1.6 (-2.3, 
5.7) 
     Rhabdomyosarcoma -0.3 (-3.9, 3.5)  N/A 1 
0.2 (-4.0, 
4.5)  
     Other specified 4.0* (0.5, 7.6)  N/A 1 4.0* (-0.1, 
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8.2)  
X. GONADAL & GERM CELL NEOPLASMS 2.4* (0.1, 4.9) 5.3* (1.3, 9.6) 
1.1 (-1.3, 
3.7) 
XI. CARCINOMAS & EPITHELIAL NEOPLASMS 1.9 (-0.1, 3.9) 1.8 (-1.6, 5.3) 
1.8 (-0.9, 
4.5) 
XII. OTHER & UNSPECIFIED NEOPLASMS 0.6 (-1.9, 3.2) 0.8 (-2.7, 4.4) 
-0.8 (-3.8, 
2.3) 
All Cancer Groups 1.2 (0.8, 1.7) 
1990-1999: -1.0 (-
2.9, 0.9) 
1999-2003: 6.0 (-
3.8, 16.7) 
2003-2007: -2.1 (-
10.6, 7.3) 
2007-2011: 8.0* 
(0.6, 15.9) 
1.0 (0.3, 
1.7) 
* p < 0.05 
1More than three half-case corrections would be needed for years without any cases, so APC was 
not computed 
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TABLE 4 Five-year relative survival (% (95% CI)) for ICCC groups and subgroups by age at diagnosis, decade of 
diagnosis, and sex 
 
ICCC Group 
Overal
l 
Age at Diagnosis 
Decade of 
Diagnosis 
Sex 
0-4 5-9 10-14 15-19 
1990-
2000 
2001-
2011 
Male Female 
I. LEUKEMIAS 
36.5 
(33.4, 
40.0) 
44.0 (38.7, 
50.0) 
37.3 (31.0, 
44.8) 
35.0 (28.6, 
42.7) 
22.4 
(16.7, 
30.0) 
30.6 
(26.7, 
35.1) 
43.7 
(38.9, 
49.0) 
34.3 
(30.2, 
38.8) 
39.7 
(34.8, 
45.2) 
     ALL 
44.2 
(40.0, 
48.7) 
48.6 (42.2, 
55.9) 
42.5 (34.9, 
51.7) 
49.4 (40.7, 
59.9) 
21.8 
(13.3, 
35.5) 
38.3 
(33.1, 
44.2) 
52.3 
(46.0, 
59.4) 
41.4 
(36.1, 
47.4) 
48.2 
(41.9, 
55.6) 
     AML 
22.1 
(17.0, 
28.8) 
23.6 (15.1, 
36.9) 
29.0 (17.4, 
48.3) 
16.3 (8.6, 
30.8) 
21.6 
(13.5, 
34.7) 
16.0 
(9.9, 
25.8) 
26.5 
(19.5, 
36.1) 
20.2 
(14.0, 
29.1) 
24.5 
(16.9, 
35.4) 
     Unspecified 
29.7 
(21.8, 
40.3) 
51.8 (38.0, 
70.8) 
17.5 (7.4, 
41.6) 
22.4 (9.5, 
52.8) 
14.6 (6.3, 
33.8) 
23.1 
(14.7, 
36.3) 
39.3 
(26.4, 
58.4) 
26.3 
(16.7, 
41.4) 
32.9 
(21.7, 
49.7) 
II. LYMPHOMAS 
49.3 
(43.3, 
56.0) 
57.7 (44.5, 
74.8) 
57.9 (45.7, 
73.4) 
52.1 (41.3, 
65.6) 
40.5 
(31.8, 
51.6) 
44.0 
(36.6, 
53.0) 
53.1 
(43.9, 
64.3) 
47.8 
(40.5, 
56.6) 
51.3 
(42.1, 
62.6) 
     Hodgkin lymphoma 
67.8 
(54.6, 
84.3) 
100.2 
(100.2, 
100.2) 
75.3 (54.0, 
105.0) 
81.8 (60.9, 
109.9) 
53.4 
(35.0, 
81.7) 
74.0 
(57.2, 
95.6) 
60.6 
(41.7, 
88.0) 
64.7 
(50.1, 
83.6) 
89.0 
(75.9, 
104.3) 
     Non-Hodgkin 
lymphoma 
46.6 
(39.0, 
55.5) 
46.8 (28.1, 
77.8) 
48.3 (33.3, 
70.0) 
49.0 (35.6, 
67.4) 
43.8 
(33.4, 
57.4) 
43.3 
(33.3, 
56.4) 
49.1 
(38.6, 
62.4) 
44.5 
(35.1, 
56.6) 
49.3 
(38.0, 
64.1) 
     Burkitt lymphoma 
41.8 
(25.4, 
68.8) 
53.6 (29.9, 
95.9) 
64.2 (42.4, 
97.3) 
0.0 (0.0, 
0.0) 
0.0 (0.0, 
0.0) 
15.4 
(5.1, 
47.0) 
77.0 
(58.0, 
102.4) 
41.7 
(24.1, 
72.2) 
33.3 
(10.3, 
108.2) 
     Unspecified 
33.4 
(21.0, 
53.1) 
57.3 (28.2, 
116.7) 
33.3 (10.3, 
108.3) 
35.2 (17.3, 
71.7) 
25.7 
(12.2, 
54.1) 
30.5 
(17.6, 
52.8) 
45.3 
(24.8, 
83.1) 
35.7 
(20.1, 
63.5) 
31.0 
(14.9, 
64.6) 
III. BRAIN AND SPINAL 
NEOPLASMS 
34.1 
(29.0, 
40.0) 
20.0 (12.0, 
33.4) 
34.7 (26.1, 
46.1) 
40.3 (31.0, 
52.4) 
39.4 
(28.6, 
54.3) 
36.7 
(29.8, 
45.3) 
31.6 
(24.7, 
40.5) 
32.4 
(25.7, 
40.8) 
35.9 
(28.7, 
44.9) 
     Astrocytomas 34.5 
(25.6, 
27.5 (13.1, 
58.1) 
34.9 (19.3, 
63.1) 
40.3 (24.6, 
66.1) 
33.2 
(18.8, 
42.3 
(29.6, 
26.6 
(16.0, 
35.5 
(23.3, 
33.1 
(21.7, 
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46.4) 58.8) 60.3) 44.2) 54.0) 50.4) 
     PNETs and 
medulloblastoma 
29.3 
(20.6, 
41.6) 
19.4 (8.9, 
41.9) 
37.4 (22.9, 
61.0) 
35.0 (20.4, 
60.1) 
0.1 (0.0, 
0.5) 
31.2 
(20.2, 
48.1) 
27.6 
(15.8, 
48.4) 
28.8 
(17.7, 
46.7) 
30.6 
(18.8, 
49.9) 
     Unspecified 
32. 
(24.4, 
42.4) 
0.0 (0.0, 
317.1) 
32.4 (20.0, 
52.6) 
41.5 (27.6, 
62.5) 
36.5 
(22.0, 
60.7) 
35.8 
(25.5, 
50.3) 
28.7 
(18.3, 
45.0) 
25.2 
(16.3, 
39.1) 
40.8 
(29.8, 
55.9) 
IV. NEUROBLASTOMAS 
20.6 
(12.7, 
33.3) 
21.5 (12.2, 
38.0) 
14.5 (4.8, 
43.7) 
100.2 
(100.2, 
100.2) 
16.7 (4.2, 
6.6) 
15.9 
(7.8, 
32.4) 
27.6 
(151.2, 
50.2) 
9.0 (2.9, 
27.5) 
29.3 
(17.9, 
47.9) 
V. RETINOBLASTOMAS 
59.5 
(47.9, 
73.8) 
58.7 (46.6, 
74.0) 
60.0 (32.1, 
112.5) 
100.1 
(100.1, 
100.1) 
NA 
57.2 
(40.8, 
80.2) 
61.2 
(46.7, 
80.3) 
53.1 
(36.5, 
77.2) 
64.3 
(49.9, 
82.8) 
VI. RENAL TUMORS 
71.1 
(61.1, 
82.7) 
78.9 (69.3, 
90.0) 
43.0 (20.8, 
88.7) 
50.0 (18.8, 
133.3) 
33.4 
(10.3, 
108.5) 
62.9 
(46.9, 
84.5) 
75.7 
(63.9, 
89.8) 
79.8 
(67.2, 
94.9) 
62.3 
(48.3, 
80.4) 
VII. HEPATIC TUMORS 
25.6 
(15.7, 
41.6) 
35.9 (19.1, 
67.2) 
0.0 (0.0, 
0.0) 
37.6 (16.9, 
83.7) 
19.9 (8.8, 
44.8) 
25.8 
(13.6, 
48.9) 
27.6 
(15.2, 
50.2) 
30.1 
(18.1, 
50.3) 
17.3 (6.5, 
46.4) 
VIII. MALIGNANT BONE 
TUMORS 
27.4 
(20.5, 
36.7) 
75.3 (52.0, 
109.2) 
12.9 (3.7, 
44.9) 
22.9 (13.7, 
38.3) 
28.9 
(19.2, 
43.5) 
30.3 
(21.0, 
43.6) 
23.3 
(14.4, 
37.9) 
25.1 
(17.1, 
37.0) 
30.7 
(20.8, 
48.5) 
IX. SOFT TISSUE 
SARCOMAS 
47.4 
(38.1, 
56.5) 
41.5 (28.1, 
61.3) 
55.7 (34.1, 
91.2) 
49.1 (34.7, 
69.5) 
41.9 
(28.5, 
61.6) 
43.4 
(32.5, 
58.0) 
48.6 
(37.2, 
63.3) 
39.3 
(28.6, 
54.2) 
52.9 
(41.5, 
67.4) 
     Rhabdomyosarcoma 
28.5 
(18.7, 
43.5) 
35.5 (20.8, 
60.7) 
31.2 (12.3, 
79.0) 
20.9 (7.5, 
58.4) 
13.7 (3.7, 
50.8) 
29.6 
(17.2, 
51.2) 
26.7 
(13.9, 
51.1) 
23.4 
(12.3, 
44.4) 
34.2 
(20.0, 
58.3) 
     Other specified 
72.4 
(59.7, 
87.8) 
55.8 (32.5, 
95.8) 
100.2 
(100.2, 
100.2) 
75.9 (52.3, 
110.1) 
73.3 
(57.9, 
92.7) 
63.7 
(45.2, 
89.8) 
79.5 
(65.5, 
96.7) 
67.4 
(49.4, 
91.9) 
77.8 
(62.9, 
96.2) 
X. GONADAL AND 
GERM CELL NEOPLASMS 
64.5 
(57.7, 
72.0) 
44.3 (27.4, 
71.4) 
78.7 (60.5, 
102.5) 
61.9 (49.7, 
77.1) 
67.7 
(58.7, 
78.1) 
66.1 
(57.1, 
76.5) 
63.4 
(53.9, 
74.6) 
48.0 
(35.9, 
64.3) 
70.8 
(63.3, 
79.4) 
XI. MALIGNANT 
EPITHELIAL NEOPLASMS 
61.1 
(55.0, 
67.9) 
31.4 (14.2, 
69.4) 
57.7 (39.5, 
84.2) 
74.1 (62.9, 
87.3) 
58.5 
(50.9, 
67.3) 
58.7 
(50.3, 
68.6) 
63.4 
(55.0, 
73.2) 
40.8 
(32.0, 
52.0) 
75.6 
(68.4, 
83.6) 
XII. OTHER AND 
UNSPECIFIED 
NEOPLASMS 
51.9 
(42.3, 
63.7) 
56.4 (42.0, 
75.7) 
62.6 (34.7, 
112.8) 
39.0 (18.2, 
83.6) 
50.9 
(37.9, 
68.4) 
40.2 
(27.1, 
59.7) 
59.2 
(47.0, 
74.7) 
57.3 
(44.5, 
73.7) 
45.4 
(32.2, 
63.9) 
All Cancer Groups 43.1 
(41.1, 
44.4 (40.7, 40.7 (36.2, 44.3 (40.3, 
42.5 
(39.0, 
39.4 
(36.7, 
47.2 
(44.3, 
37.7 
(35.0, 
49.2 
(46.3, 
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45.2) 48.4) 45.7) 48.8) 46.4) 42.2) 50.3) 40.5) 52.2) 
 
 
